Comparison of RARS-T patients according to diagnosis of ET and expression of JAK2-V617F
. | All patients . | . | Patients with ET features . | . | ||
|---|---|---|---|---|---|---|
. | No evidence of ET, n = 8 . | ET features, n = 8 . | JAK2-V617F negative, n = 3 . | JAK2-V617F positive, n = 5 . | ||
| BM histology in favor of ET | 0/3 | 7/7 | 3/3 | 4/4 | ||
| Male/female | 5/3 | 4/4 | 2/1 | 2/3 | ||
| Age | ||||||
| Mean ± SD | 78 ± 6 | 74 ± 8 | 72 ± 6 | 74 ± 10 | ||
| Median (range) | 79 (68-88) | 73 (59-85) | 71 (67-79) | 74 (59-85) | ||
| Sideroblasts, % | ||||||
| Mean ± SD | 69 ± 15 | 35* ± 11 | 38 ± 2 | 33 ± 14 | ||
| Median (range) | 70 (44-91) | 37 (15-50) | 38 (36-40) | 30 (15-50) | ||
| Hemoglobin, g/L | ||||||
| Mean ± SD | 98 ± 11 | 96 ± 20 | 102 ± 26 | 93 ± 17 | ||
| Median (range) | 100 (75-115) | 88 (75-133) | 88 (86-133) | 88 (75-120) | ||
| Platelets, × 109/L | ||||||
| Mean ± SD | 623 ± 170 | 957† ± 346 | 966 ± 385 | 951 ± 367 | ||
| Median (range) | 563 (450-880) | 943 (546-1478) | 928 (600-1369) | 958 (546-1478) | ||
| Leukocytes, × 109/L | ||||||
| Mean ± SD | 8.5 ± 2.9 | 11.4 ± 3.7 | 9.7 ± 2.2 | 12.4 ± 4.2 | ||
| Median (range) | 8.0 (5.3-13.6) | 10.9 (7.4-17.5) | 10.0 (7.4-11.8) | 12.9 (8.0-17.5) | ||
. | All patients . | . | Patients with ET features . | . | ||
|---|---|---|---|---|---|---|
. | No evidence of ET, n = 8 . | ET features, n = 8 . | JAK2-V617F negative, n = 3 . | JAK2-V617F positive, n = 5 . | ||
| BM histology in favor of ET | 0/3 | 7/7 | 3/3 | 4/4 | ||
| Male/female | 5/3 | 4/4 | 2/1 | 2/3 | ||
| Age | ||||||
| Mean ± SD | 78 ± 6 | 74 ± 8 | 72 ± 6 | 74 ± 10 | ||
| Median (range) | 79 (68-88) | 73 (59-85) | 71 (67-79) | 74 (59-85) | ||
| Sideroblasts, % | ||||||
| Mean ± SD | 69 ± 15 | 35* ± 11 | 38 ± 2 | 33 ± 14 | ||
| Median (range) | 70 (44-91) | 37 (15-50) | 38 (36-40) | 30 (15-50) | ||
| Hemoglobin, g/L | ||||||
| Mean ± SD | 98 ± 11 | 96 ± 20 | 102 ± 26 | 93 ± 17 | ||
| Median (range) | 100 (75-115) | 88 (75-133) | 88 (86-133) | 88 (75-120) | ||
| Platelets, × 109/L | ||||||
| Mean ± SD | 623 ± 170 | 957† ± 346 | 966 ± 385 | 951 ± 367 | ||
| Median (range) | 563 (450-880) | 943 (546-1478) | 928 (600-1369) | 958 (546-1478) | ||
| Leukocytes, × 109/L | ||||||
| Mean ± SD | 8.5 ± 2.9 | 11.4 ± 3.7 | 9.7 ± 2.2 | 12.4 ± 4.2 | ||
| Median (range) | 8.0 (5.3-13.6) | 10.9 (7.4-17.5) | 10.0 (7.4-11.8) | 12.9 (8.0-17.5) | ||
Characteristics of RARS patients with thrombocytosis (RARS-T) were first analyzed depending on whether ET features had been established (by bone marrow histology [7 patients] and/or presence of the JAK2-V617F mutation [5 patients]) or not (absence of JAK2-V617F and bone marrow histology not in favor of ET, or not available). Then RARS-T patients with ET features were compared according to the presence of JAK2-V617F
P < .001
P = .028, compared to patients with no evidence of ET, by Student t test